SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics

Area of Science:

• Virology
• Immunology
• Pathology

Background:

• SARS-CoV-2 enters airways, infects cells, and replicates.
• COVID-19 can cause severe lung damage, cytokine storms, and impaired gas exchange.
• Impaired metabolic health (IMH), including diabetes and cardiovascular disease, is linked to severe COVID-19 and mortality.

Purpose of the Study:

• To review the impact of SARS-CoV-2 on tissue damage, particularly in the lungs, heart, and kidneys.
• To analyze pathophysiological changes and the role of impaired metabolic health in COVID-19 severity.
• To identify potential therapeutic targets and drugs for COVID-19 treatment.

Main Methods:

• Literature review of studies on SARS-CoV-2 infection, COVID-19 pathology, and metabolic health.
• Analysis of data on patient demographics, comorbidities, and disease outcomes.
• Identification of molecular mechanisms and therapeutic strategies.

Main Results:

• SARS-CoV-2 infection leads to significant tissue damage, including alveolar cell damage and impaired oxygen exchange.
• Patients with pre-existing conditions like diabetes, cardiovascular disease, and older age face higher mortality risks.
• ACE-2 receptor expression influences viral entry and infection severity.

Conclusions:

• Impaired metabolic health is a critical factor exacerbating COVID-19 severity and mortality.
• Understanding tissue damage and pathophysiological changes is crucial for developing targeted therapies.
• Further research into therapeutic targets and drug repurposing is needed to combat COVID-19 effectively.